Save the Date: Orion’s Capital Markets Day on 22 May 2025

Orion b

45.00 CHF 12.09%

• Charts
• News
• Analysen

Kaufen Verkaufen

ORION CORPORATION
INVESTOR NEWS
10 FEBRUARY 2025 at 14.00 EET          

        
Save the Date: Orion’s Capital Markets Day on 22 May 2025

Orion will hold a Capital Markets Day for analysts, institutional investors, bankers and media representatives in Helsinki on 22 May 2025 in the afternoon.

During the afternoon, Orion’s President & CEO, Liisa Hurme, CFO René Lindell, and other members of the Executive Management Board will discuss Orion’s growth strategy, financial objectives and businesses. Attendees will have the opportunity to ask questions during the event.

Orion’s Capital Markets Day is held at the event studio Eliel at Sanomatalo (Töölönlahdenkatu 2, 00100 Helsinki, Finland) with a remote participation possibility. The webcast link and presentation materials will be published on Orion’s investor website at a later date.

A formal invitation including an agenda and registration details will be published closer to the event date.

                                                 
Contact person:
Tuukka Hirvonen, Investor Relations

tel. +358 10 426 2721 

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orionpharma.com

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2023 amounted to EUR 1,190 million and the company had about 3,600 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.